UBS Group’s Icosavax, Inc. Common Stock ICVX Stock Holding History

UBS Group’s Portfolio ICVX Stock Details ICVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-256,869	Closed	-$4.05M	–	10370
2023 Q4	$4.05M	Buy	256,869 +242,325	+1,666%	+$2.33M	﹤0.01%	3008
2023 Q3	$113K	Buy	14,544 +7,183	+98%	+$59.6K	﹤0.01%	5757
2023 Q2	$73.1K	Buy	7,361 +6,812	+1,241%	+$54.5K	﹤0.01%	6238
2023 Q1	$3.18K	Sell	549 -2,549	-82%	-$22K	﹤0.01%	8360
2022 Q4	$24.6K	Sell	3,098 -172,012	-98%	-$738K	﹤0.01%	7434
2022 Q3	$553K	Sell	175,110 -15,378	-8%	-$96.2K	﹤0.01%	4248
2022 Q2	$1.09M	Buy	+190,488	New	+$1.49M	﹤0.01%	3664

UBS Group's ICVX Position: Q1 2024 in Review

UBS Group sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2024, closing a stake of 256,869 shares — an estimated $4.05M sold.

UBS Group first reported a position in ICVX in Q2 2022 and held it in 7 quarters. The position peaked at $4.05M in Q4 2023. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.

UBS Group reported no remaining Icosavax, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS Group sold 256,869 Icosavax, Inc. Common Stock shares in Q1 2024, an estimated $4.05M.
UBS Group first reported a position in Icosavax, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
UBS Group's Icosavax, Inc. Common Stock position peaked at $4.05M in Q4 2023.
0 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.